12:00 AM
 | 
Jul 27, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VEGF Trap-Eye: Completed Phase II enrollment

Regeneron completed enrollment of 200 patients in the double-blind, active-controlled, international Phase II DA VINCI trial comparing 4 dosages of intravitreal VEGF Trap-Eye vs. laser treatment. Regeneron and Bayer have commercialization...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >